Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin), one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
Information about the article:
Title: Hemolysis From Ceftriaxone
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1144
Article Code: 1144b
Date: November 25, 2002
Volume: 44
Pages: 100-101